ABOUT SOLENO
Soleno is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
OUR SCIENCE
The Company’s lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program.
OUR PROGRAMS
We are focused on developing innovative therapeutic options to address the most burdensome aspects of Prader-Willi syndrome (PWS).
INVESTORS
Soleno is committed to maximizing shareholder value by developing and commercializing innovative therapeutic products with the goal of improving the lives of individuals living with complex, life-threatening rare diseases with unmet medical needs.
Developing novel therapeutics for the treatment of rare diseases